ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.
All News
Article
Article
Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or worsening of their autoimmune disease.
David Liew
Tweet
In the @ACRheum MSK Ultrasound Guidance:
In difficult-to-treat RA, MSUS can distinguish symptoms of active synovitis from other sources of pain.
(consensus: mod)
CURRENTLY do you often use ultrasound when RA gets difficult to treat, and synovitis isn't obvious? #ACR24 @RheumNow
David Liew
Tweet
One situation I've seen MSK ultrasound have impact ++ in the real-world is showing patients their own RA disease activity.
Arthritis might be the invisible disease sometimes, but seeing it in full Doppler colour on screen means a lot to many.
#ACR24 MSK USS Guidance @RheumNow https://t.co/wd9s6FAfp4
David Liew
Tweet
The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it).
https://t.co/GZ7tZ6fNMK
Great for all US rheumatologists, but also very handy for all of us globally
#ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR
RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE
Race of b/tsDMARDs in RA, the “JAK-pot” study.
JAKi and TNFi with more rapid early improvement in CDIA, HAQ, and pain compared to ABA or IL-6 inhibitors…..although effects blunted after adjusting for patient and RA characteristics
#ACR24 @RheumNow ABST#0501 https://t.co/8M4wX3LAbW
How does #cardiovascular risk vary with #ACPA & #biologics in #RA?
⬆️BMI assoc with ⬆️MACE risk in ACPA+ pts
In ACPA- pts, BMI inversely assoc with MACE risk among pts on biologics
Further evidence to consider ACPA, BMI & MACE as part of RA management
Ab0870 #ACR24 @RheumNow https://t.co/UkkC146DWS
Cross-sectional study finds metabolic dysregulation in RA-ILD is indicative of poor prognosis- FGF-21 assoc w. poor survival.
Another link btwn CV risk factors, metabolic syndrome & RA? Should we be doing more to manage metabolic risk factors in RA-ILD?
Ab0803 #ACR24 @RheumNow
Not just the presence but higher levels of biomarkers predict RA-ILD progression.
#ACR24 @RheumNow ABST#0804 https://t.co/5jhBjXDUeY
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs?
≥5% weight loss, after taking a med, led to better disease activity & QoL
Data may inform RCTs to explore effect of these meds in RMDs
Ab0845 #ACR24 @RheumNow
Don’t miss the “window of opportunity” for aggressive treatment in early RA!
with active RA, risk of ILD 6x and RA-related lung disease 4x higher
#ACR24 @RheumNow ABST#0802 https://t.co/yxlfInte6A
What's the assoc between RA disease activity & ILD?
Results @MassGenBrigham show early active RA is assoc with
➡️6x incr risk of #ILD
➡️4x incr risk of RA-related lung disease
Early DMARDs are vital to reduce articular & extra-articular manifestations!
Ab0802 #ACR24 @RheumNow
Richard Conway
Tweet
McDermott @jeffsparks et al. SAIL-RA prospective study. 172 early RA patients. RA lund disease in 16%, RA-ILD in 11%. Disease activity strongest predictor RA lung disease, HR 4.89, and RA-ILD, HR 6.17. @RheumNow #ACR24 Abstr#0802 #ACRbest https://t.co/ia0koG64mL https://t.co/U1KdgcUfOy
Eric Dein
Tweet
Ab#0427 #ACR24
HSS: menopause & systemic rheum disease severity
1/3 women report worse disease associated w menopause
Reported more flares, menopausal symptoms
Findings were similar between SLE and RA, but SLE patients were >2x more likely to discuss w their rheum
@RheumNow
❔Can rheum drugs have beneficial effects on cognition?
💊Possible benefits with MTX and TNFis but certainly an active area of research and more studies needed
#ACR24 @RheumNow https://t.co/lCnIRLwNjK
Eric Dein
Tweet
Ab#474 #ACR24
Hsieh and @NamrataRheum
Cancer Survival in RA
Unable to do meta-analysis due to lack of data
HR for lung cancer in RA 1.04
No clear evid of increased risk, but more data and studies needed
Great research project by a high school student (!!)
@RheumNow https://t.co/Sfrf2v2UO4
Eric Dein
Tweet
Ab#0458 #ACR24
10 year outcomes of 176 patients with seroneg RA
32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1)
40 (23%) had drug-free remission
30 (17%) started b/tsDMARD
@RheumNow
👴🏼 Ageing & RMDs at #ACR24
🧠 14 factors associated with dementia
❗️Justin Levenson tells us that if we could address all of these, we could reduce dementia risk by 45%!
@RheumNow https://t.co/SgC5KMohXy
Antoni Chan MD (Prof)
Tweet
Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB
